Issues at Novo Nordisk lead to shortage of fast-acting diabetes drug

The Danish Medicines Agency has reported that it is currently difficult to find diabetes drug Novorapid in Denmark.

Photo: Jacob Ehrbahn/Politiken

There is a current shortage of Novo Nordisk’s fast-acting diabetes drug Novorapid 100 E/ml in Denmark, the Danish Medicines Agency has announced.

Novorapid is a subcutaneous form of fast-acting insulin aspart that is administered via injection pen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs